Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects

Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects is an open dataset from Health Canada with 2 files (HTML); catalogue record updated 2024-05-10. On CanQuery you can follow the original downloads. Files are available in English and French.

The minerals stored within the bones help provide strength. Bones that have fewer minerals (less bone mineral density) are more likely to become brittle and break (fracture). A safety review was carried out by Health Canada to evaluate the risk of bone-related side effects of using SGLT2 inhibitors. The review was triggered by a notice about international reports of bone-related side effects experienced in patients taking the SGLT2 inhibitor canagliflozin.

Publisher
Health Canada
Resources
2
Catalogue metadata updated
2024-05-10

Data overview

Formats
HTML
File languages
English, French

Official sources and licences

Resources

Related open data